Cargando…
Novel TLR7/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells
Antiretroviral therapy can successfully suppress HIV-1 replication to undetectable levels but fails to eliminate latent and persistent HIV-1 reservoirs. Recent studies have focused on the immunomodulatory agents such as Toll-like receptor 7 and 8 (TLR7 and TLR8) capable of activating, thereby render...
Autores principales: | Li, Yangyang, Wang, Zhisong, Hou, Ying, Liu, Xiaoyu, Hong, Junxian, Shi, Xuanling, Huang, Xiaojie, Zhang, Tong, Liao, Xuebin, Zhang, Linqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911797/ https://www.ncbi.nlm.nih.gov/pubmed/36778871 http://dx.doi.org/10.3389/fmicb.2023.1033448 |
Ejemplares similares
-
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021) -
Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8
por: Wang, Xiaoyu, et al.
Publicado: (2022) -
The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022) -
TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
por: Lu, Hailing, et al.
Publicado: (2013) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)